Trials / Completed
CompletedNCT00524329
Esomeprazole And Symptomatic Response In Patients With Or Without An Elevated Risk For Non-Steroidal Anti-Inflammatory Drug (NSAID)-Associated GI Damage
SYNCHRONISE: Esomeprazole 20 mg Once Daily for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs Including COX-2 Selective NSAIDs in Dutch General Practice: The Influence of Risk-Factors for NSAID-Associated GI Damage on Sympton Response
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,220 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the treatment effect in patients with upper gastro-intestinal complaints with an elevated risk for NSAID-associated GI-damage to those without an elevated risk for NSAID-associated damage (as determined by the treating physician).
Conditions
Timeline
- Start date
- 2006-01-01
- Primary completion
- 2007-03-01
- Completion
- 2007-10-01
- First posted
- 2007-09-03
- Last updated
- 2008-09-26
Source: ClinicalTrials.gov record NCT00524329. Inclusion in this directory is not an endorsement.